Baxter International Inc. (BAX)

Over the past six months, Baxter International Inc.'s stock price has experienced a decline. As of July 18, 2025, the share price was $27.77, representing a 21.44% decrease from July 19, 2024. Over the last six months, the stock has fallen by 12.53%. The stock has also seen a 7.05% fall over the last month and a 2.39% fall compared to the previous week. The company's market capitalization as of July 22, 2025, is approximately $14.05 billion, a decrease of 2.82% over the last week. Key events impacting the stock include planned divestitures, profitability challenges, inflationary pressures and supply chain issues, a high dividend payout ratio, management changes, and new US tariffs.

Demand for Baxter's products and services is largely dependent on overall demand in the healthcare market. Demand levels can vary in response to macro-economic conditions, regulatory requirements, natural disasters, pandemics, epidemics and competitive dynamics. The company's ability to match production levels to market demand is imprecise, which can lead to either a failure to meet demand or an oversupply of inventory.

Baxter International Inc. is an American multinational healthcare company headquartered in Deerfield, Illinois, operating in the Medical Equipment, Supplies & Distribution sector. The company focuses on products designed to treat chronic and acute medical conditions, serving various healthcare facilities and patients at home. Baxter's business is structured across three main segments: Medical Product and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. Its product portfolio includes renal care, medication delivery, pharmaceuticals, advanced surgery technologies, healthcare systems and technologies, and clinical nutrition.

Baxter International Inc. has a significant global presence, operating in over 110 countries with manufacturing facilities in 27 countries. The company's operational framework includes a global manufacturing and supply chain network across North America, Europe, Asia, and Latin America. In 2022, the geographic revenue breakdown was 52% from the United States, 22% from Europe, 18% from Asia-Pacific, and 8% from other regions. Export sales account for 52.7% of its net sales.

Baxter's brand reputation is generally associated with being a reliable supplier of essential medical products and a global leader in medical technology. However, certain events have affected Baxter International Inc.'s reputation in the past year. These include regulatory scrutiny, supply chain vulnerabilities, a poorly valued divestiture, and execution challenges.

Baxter International Inc. has significant institutional ownership, with approximately 85.98% of the company owned by institutional investors. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, and Dodge & Cox. Third Point LLC is noted as the largest individual shareholder, owning 76.86 million shares, representing 14.98% of the company.